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AMP: adenosine monophosphate 
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CVP: central venous pressure  
DCD: donation after cardiac death 
ELISA: enzyme-linked immunosorbent assay  
IL: interleukin 
IRI: ischemia reperfusion injury 
LAP: left atrial pressure  
MPO: myeloperoxidase 
PAP: pulmonary artery pressure  
TNF: tumor necrosis factor 
WDR: wet-to-dry weight ratio  
WIT: warm ischemic time 
Abstract 
Background: It is a matter of great importance in a donation after cardiac death 
to attenuate ischemia reperfusion injury (IRI) related to the inevitable warm 
ischemic time. Methods: Donor dogs were rendered cardiac-dead and left at 
room temperature. The dogs were allocated into two groups: the beta-2 group (n 
= 5) received an aerosolized beta-2 adrenoreceptor agonist (procaterol 350μg) 
and ventilation with 100% oxygen for 60 min starting at 240 min after cardiac 
arrest, and the control group (n = 6) received an aerosolized control solvent with 
the ventilation. Lungs were recovered 300 min after cardiac arrest. The recipient 
dogs underwent left single lung transplantation to evaluate the functions of the 
left transplanted lung for 240 min after the reperfusion. Results: In the beta-2 
group, the oxygenation and dynamic compliance were significantly higher than 
the control group. The beta-2 group revealed significantly higher levels of cyclic 
adenosine monophostates and high-energy phosphates in the donor lung after 
the inhalation compared to before it. Furthermore, the histological findings 
revealed that the beta-2 group had less edema and fewer inflammatory cells. 
Conclusion: Our results suggest that beta-2 adrenorecptor agonist inhalation 
during the pre-procurement period may ameliorate IRI. 
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One method of countering chronic lung donor shortages is the practice of 
donation after cardiac death (DCD). This technique inevitably leads to ischemia 
reperfusion injury (IRI) related to warm ischemia. However, DCD is now 
increasingly accepted in some countries. 
Beta-2 agonists in humans, injected intravenously or aerosolized and 
administered through the airway, were reported to have protective effects 
against high altitude lung edema 1, ARDS 2, pulmonary edema after lung 
resection 3 and pulmonary edema of discarded lungs from brain-dead donors in 
an ex vivo model 4. Moreover, beta-2 agonists have already been reported to 
have protective effects against IRI in rat models, including a study by our group 5. 
Therefore, we hypothesized that a beta-2 adrenoreceptor agonist would 
ameliorate IRI in our canine model. 
 
 
Materials and Methods 
Animals 
Eleven pairs of weight-matched TOYO Beagles (8.55-10.65 kg, Kitayama Labes 
Co. Ltd., Hongo Farm, Yamaguchi, Japan) were used in this study. All animals 
received humane care in compliance with the Principles of Laboratory Animal 
Care, formulated by the National Society for Medical Research, and the Guide 
for the Care and Use of Laboratory Animals, prepared by the Institute of 
Laboratory Animal Resources and published by the National Institutes of Health 
(NIH Publication No. 86-23, revised 1996). The study protocol was approved by 




Donor dogs were anesthetized via an intramuscular injection of midazolam (0.5 
mg/kg), xylazine (0.25 mg/kg), and atropine sulfate (0.05 mg/kg). They were 
then intubated and mechanically ventilated at a tidal volume of 25 ml/kg and a 
rate of 15 breaths/min. The positive end-expiratory pressure was 5.0 cm H2O; 
the inspired O2 fraction was 1.0. They were euthanized via the intravenous 
administration of potassium chloride (0.5 mEq/kg), without heparinization. The 
ventilators were removed, and the tracheal tubes were left open to room air. All 
donors were left at room temperature (21°C) for 300 min. The beta-2 group (n = 
5) received inhalation of the beta-2 adrenoreceptor agonist (3.5ml of 0.01% 
pocaterol inhalation solution (350μg of procaterol)) during ventilation with 100% 
oxygen for 60 min starting at 240 min after cardiac arrest. The control group (n = 
6) receive inhalation of the control solvent (3.5ml) with the same ventilation 
setting as the beta-2 group. The inhalation solution and the control solvent were 
aerosolized by a nebulizer (Aeroneb Professional Nebulizer System, Aerogen, 
Ireland) which was inserted into the inspiratory loop of a ventilator. A pulmonary 
arterial flush was performed on all donors at 300 min after the cardiac arrest, 
using ET-Kyoto solution (Otsuka Pharmaceutical Co. Ltd. Tokyo, Japan), an 
extracellular preservation solution that we originally developed for clinical lung 
transplantation 6. Prior to use, the ET-Kyoto solution was stored at 4°C without 
heparin. For the antegrade flush, we used 100 ml/kg; 50 ml/kg was used for the 
retrograde flush. Both were performed from 30 cm above the donors’ chests. 
Ventilation was performed during the flush. The recovered organs, semi-inflated 
(within 20 cm H2O) with 100% oxygen, were preserved at 4°C for 120 min.  
 
Recipient preparation and transplantation 
Recipient dogs were anesthetized, maintained, and ventilated in the same 
manner as the donors. Peak inspiratory pressure was monitored by a pressure 
transducer that was attached to the tracheal tube. For each recipient, a 5F 
thermodilution catheter (151F7, Edwards Lifesciences, Irvine, CA, USA) was 
placed in the main pulmonary artery from the right femoral vein to measure 
pulmonary artery pressure (PAP), central venous pressure (CVP), and cardiac 
output (CO). A femoral arterial line was inserted for measuring aortic pressure 
(AoP) and for arterial blood gas analysis. After thoracotomy, a 2.0-mm catheter 
was inserted directly into the left atrium for monitoring left arterial pressure (LAP). 
We then performed a left pneumonectomy and left lung transplantation. The right 
pulmonary artery was encircled with vascular tape and clamped with a tourniquet 
continuously from 60 min to 240 min after reperfusion in order to evaluate the 
function of the transplanted left lung. 
 
Definitions 
The warm ischemic time (300 min) was defined as the time from cardiac arrest to 
the pulmonary arterial flush. The cold ischemic time (120 min) was defined as 
the time from the initiation of the flush of the donor lung until the lung was 
removed from cold storage for transplantation. The transplantation time (60 min) 
was defined as the time from the removal of the lung from storage to the 
reperfusion after we performed transplantation. Therefore, the total ischemic 
time was defined as the sum, 480 min.  
 
Assessment of the lungs and their function  
Arterial and pulmonary arterial blood samples were taken in order to analyze the 
blood gases with a blood gas analyzer (iSTAT Portable Clinical Analyzer, iSTAT 
Corp., East Windsor, NJ, USA). 
 Wet-to-dry lung weight ratio 
Left lung tissues (100-300 mg) were used to calculate the wet-to-dry weight ratio 
(WDR) at 240 min after reperfusion or at death. The tissues were excised from 
the tip of the lung and the cut end was closed by ligation. Wet weight (mg) was 
measured first; dry weight (mg) was measured after the tissue had been dried 
overnight at 180°C. The WDR was calculated by dividing the wet weight by the 
dry weight. 
 
Measurement of adenine nucleotide levels 
We used pieces of peripheral lung tissues collected from “normal lungs”, which 
were collected from the left lungs of recipients just after the induction of 
anesthesia. Furthermore, we used samples from donors before and after 
ventilation and from recipients at 240 min after reperfusion. We measured the 
levels of adenosine triphosphate (ATP), adenosine diphosphate (ADP), and 
adenosine monophosphate (AMP) using high-performance liquid 
chromatography (Shim-pack CLC-ODS column; 15 cm × 6.0 mm; Shimadzu, 
Japan). Total adenosine nucleotides (TAN) and the energy charge were 
calculated as previously reported 5.  
 
Measurement of cAMP levels  
We used pieces of the peripheral lung tissues from donors before and after 
ventilation to determine the cAMP levels. The levels of cAMP were measured 
with a radioimmunoassay kit (cAMP assay kit; Yamasa, Chiba, Japan) as 
previously reported 5. At the same time, protein levels were measured according 
to the method described by Lowry and coworkers 7. 
 
The macroscopic findings and histology (hematoxylin and eosin staining) 
We recorded the macroscopic appearances of the left lungs 240 min after 
reperfusion. Left lung specimens collected 240 min after reperfusion were also 
used for the histological analysis. Each lung was immersed in 10% formalin, 
embedded in paraffin, and stained with hematoxylin and eosin.  
 Naphthol AS-D chloroacetate esterase staining 
The accumulation of activated neutrophils in paraffin-embedded sections of left 
lungs harvested at 240 min after reperfusion was assessed by staining for 
chloroacetate esterase, a neutrophil-specific marker, according to the method 
described by Leder 8. Polymorphonuclear cells, identified by their staining and 
morphology, were counted in 10 randomly chosen high-power fields per section 
at an original magnification of 400×. Three separate investigators (J.S., F.C., 
and D.N.) evaluated, interpreted, and reached a consensus, without any 
knowledge of the experimental groups. 
 
Myeloperoxidase activity  
The level of myeloperoxidase (MPO) was measured in the peripheral lung 
tissues collected in recipients at 240 minutes after reperfusion. We followed the 
instructions in the manufacturer’s manuals from the MPO Assay Kit (BioVision 
Research Products, Mountain View, CA, USA). 
  
Serum cytokine levels 
We used enzyme-linked immunosorbent assays (ELISA) to measure the serum 
IL-6, IL-8, and TNF-α levels at 240 min after reperfusion in surviving animals. In 
all cases, we followed the instructions in the manufacturer’s manuals from the 
IL-6, IL-8, and TNF-α ELISA kits (Quantikine, R&D Systems Inc., Minneapolis, 
MN, USA).    
 
Statistical analyses 
All data were analyzed using the JMP® 9 software program (SAS Institute Inc., 
Cary, NC, USA). A paired t-test was used to compare the pre-ventilation and 
post-ventilation samples with or without the beta-2 agonist inhalation. An 
unpaired t-test or a repeated-measures analysis of variance (ANOVA) was used 
to explore the differences between and within the groups. The ANOVA was 
performed between 75 and 240 min in order to evaluate only the transplanted left 





Results     
There were no significant differences between the treatment groups in terms of 
the donor or recipient weights (the beta-2 group vs. the control group, donor 
weight: 10.3 ± 0.2 vs. 10.1 ± 0.3 kg; recipient weight: 9.2 ± 0.4 vs. 9.3 ± 0.2 kg). 
We set 60 min for the implantation time in our protocol, and were able to perform 
all transplants within 60 min. All 5 animals in the beta-2 group survived until the 
end-point of the study (240 min after reperfusion), while 5 out of 6 animals in the 
control group survived. The dead animal expired as the result of graft 
dysfunction between 75 and 120 min after reperfusion. 
 
Assessment of lung function  
The PaO2 at 240 min after reperfusion was 526.8 ± 130.2 vs. 112.8 ± 87.3 mmHg 
for the beta-2 group vs. the control group. Furthermore, by a repeated analysis 
of variance between groups, the PaO2 and dynamic compliance were found to 
be significantly higher in the beta-2 group than in the control group (P < 0.001 
and P = 0.013 respectively; Table 1). The cardiac output was lower and 
pulmonary vascular resistance was higher in the control group, but this 
difference did not reach significance (P = 0.087 and 0.086 respectively Table 1).  
 
Wet-to-dry lung weight ratio  
The WDR in the control group was generally higher than that in the beta-2 group 
at 240 min after reperfusion, but the difference was not significant ( 7.0 ± 2.0 
vs.9.23 ± 1.95, respectively; P = 0.11). 
 
Measurement of adenine nucleotide levels 
The control solvent inhalation did not increase the ATP levels in the control 
group (Figure 1A), while, in the beta-2 group, the ATP levels were significantly 
improved after the 60 min inhalation compared to before the inhalation (P = 
0.027; Figure 1B), Moreover, at 240 min after reperfusion, the ATP and TAN 
(TAN = ATP + ADP +AMP) levels were significantly higher in the recipient lungs 
of the beta-2 group than in the recipient lungs of the control group (P = 0.012 and 
0.027, respectively; Table 2B), and the ATP and TAN levels improved similarly to 
those in the normal lungs (Table 2A).  
 
Measurement of cAMP levels  
The control solvent inhalation did not increase the cAMP levels in the control 
group (Fig. 1C), while, in the beta-2 group, the cAMP levels were significantly 
improved after the 60 min inhalation compared to the levels before the inhalation 
(P = 0.045; Figure 1D). 
 
Macroscopic findings and histology 
At 240 min after reperfusion, the lungs from the control group macroscopically 
had dark-red areas exhibiting more patchiness than was observed in the beta-2 
group (Figures 2A, B). The histological study indicated severe intraparenchymal 
hemorrhaging and inflammation only in the control group (Figure 2C) in contrast 
to the beta-2 group (Figure 2D). 
 
Naphthol AS-D chloroacetate esterase staining 
At 240 min after reperfusion, there were significantly more polymorphonuclear 
cells in the lungs of the control group (Figure 2E) than in the beta-2 group 
(Figure 2F) (P < 0.001; Figure 2G). 
 
MPO activity 
At 240 min after reperfusion, the MPO activity levels in lung tissues were 
significantly higher in the control group than in the beta-2 group (P = 0.0058; 
Figure 3A).  
 
Serum cytokine levels 
At 240 min after reperfusion, the serum TNF-α levels were significantly higher in 
the control group than in the beta-2 group (P = 0.011; Figure 3B), while the IL-6 




In this study, we found that beta-2 adrenoreceptor agonist inhalation ameliorated 
ischemia reperfusion injury in our canine model, confirming and expanding our 
previous study in rats 5.  
 Beta-2 adrenoreceptors were reported to be distributed in alveolar cells, 
airway epithelium, airway smooth muscle, and pulmonary vessels in humans 9, 
which suggested that inhaled beta-2 agonists might have actions on various 
pulmonary tissues, especially with regard to relaxing the airway and vessels. 
Moreover, beta-2 agonists was reported to cause vasodilation and increase the 
bronchial blood flow, which arises from the aorta and forms a peribronchial 
plexus of vessels which is part of the systemic circulation 10. In addition, the 
beta-2 inotropic effect of the agonist significantly increased the cardiac output 
and pulmonary artery pressure, while decreasing the pulmonary vascular 
resistance 11. These reports may coincide with our findings, wherein we detected 
significantly higher dynamic compliance, relatively higher level of cardiac output 
(P = 0.087) and relatively lower level of pulmonary vascular resistance (P = 
0.086) in the beta-2 group, although we didn’t evaluate the compliance of only 
the transplanted left lungs because we didn’t clump the right bronchus.  
The mechanism by which the inhalation provides protection can be 
inferred from our measurements of the cAMP levels, adenine nucleotide levels, 
and inflammatory cells and cytokines. First, we found that the cAMP levels were 
significantly increased between the measurements taken before and after the 
inhalation. Beta-2 adrenoreceptor agonists were reported to decrease capillary 
permeability by increasing cAMP 12 as a result of tighter intercellular junctions 
and actomyosin myofibris relaxation 13, thereby decreasing the lung edema.   
Second, the adenosine nucleotide levels recorded herein suggest that 
the beta-2 agonist inhalation increased the energy TAN and ATP levels in the 
donor lungs, as well as the ATP and TAN levels in the recipients. A previous 
report revealed that increased TAN levels have been significantly associated 
with lung viability 14.  
Third, infiltrating leukocytes are a major factor involved in IRI 15. In the 
current study, polymorphonuclear cells with AS-D staining were less prevalent, 
and the MPO activity was lower in the beta-2 group. These findings coincide with 
reports that the systemic administration and inhalation of beta-2 adrenoreceptor 
agonists diminished neutrophil recruitment to the lungs of experimental animals. 
In terms of the mechanism, diminished intercellular cAMP in the endothelial cells 
during hypoxia is known to increase leukocyte adhesion 16, and cAMP negatively 
regulates the migratory capacity of neutrophils 17. Our findings of higher cAMP 
levels in the beta-2 group may therefore coincide with these mechanisms.  
Fourth, we observed significant decreases in the serum levels of the 
inflammatory cytokine TNF-α. In previous reports, the systemic administration of 
several beta adrenoreceptor agonists potently inhibited TNF-α during 
endotoxemia18, and inhaled salmeterol reduced TNF-α in the BALF after 
inhalation of lipopolysaccharide in humans 19. Our finding showing a reduced 
serum TNF-α level suggests that beta-2 adrenoreceptor agonist inhalation may 
reduce the inflammatory change in uncontrolled DCD donors. 
One limitation of our study is that we did not examine an adequate dose 
of procaterol in our model. Our dose, 350 μg, was likely too high, because 30 to 
50μg is clinically prescribed for one inhalation of an adult. However, frequent 
inhalation (~500μg/day) of procaterol in younger and elder adults was reported 
to be safe 20. Furthermore, we used high doses of medication in DCD donors 
240 min after cardiac arrest, which meant that there was enough long time after 
the declaration of death from the ethical aspect.  Therefore, in our experiments, 
we selected the dose of procaterol based on the likely maximum dose that could 
be used for the 60 min ventilation.  
The beta-2 adrenoreceptor agonist inhalation has not been routinely 
performed yet in brain-dead donors in Japan. One of the reasons is that it is 
difficult to change the law concerning the management of brain-dead donors in 
Japan. Now, our group has revealed the effect of beta-2 agonist inhalation in the 
experimental DCD in rat5 and this canine model. Therefore, these results would 
strongly encourage clinicians to conduct beta-2 adrenoreceptor agonist 
inhalation in brain-dead donors and, in the near future, DCD donors. 
In conclusion, we found that the protective effect of beta-2 
adrenoreceptor agonist inhalation during the last 60 min of a 300 min WIT 
preserves the lung function of DCD donors. Therefore, the use of the beta-2 
adrenoreceptor agonist inhalation during this period should be conducted in a 
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Figure Legends 
Figure 1. The ATP and cAMP levels before (pre-vent.) and after (post-vent.) the 
inhalation in donor lungs. Both the ATP and cAMP levels did not change 
significantly in the control group (A, C), while they increased significantly in the 
beta-2 group (B, D), as determined using a paired t-test.   
 
Figure 2. The results of the macroscopic (A, B) and histological (C-F) analyses 
conducted 240 min after reperfusion (hematoxylin-eosin staining(C, D), original 
magnification x 100 and naphthol AS-D chloroacetate esterase staining (E, F), x 
400). In the control group, we observed many dark-red spots (A) and alveolar 
congestion, hemorrhage, infiltration, aggregation of inflammatory cells, and 
edema (C). However, the lungs in the beta-2 group looked relatively normal (B, 
D). In naphthol AS-D chloroacetate esterase staining, subjects in the control 
group (E) possessed significantly higher numbers of polymorphonuclear cells 
than subjects in the ventilation group (F). The data are presented as the means 
± SD and were analyzed using an unpaired t-test (G).  
 Figure 3. The myeloperoxidase activity of lung tissues (A) and the serum 
cytokine levels (B-D) in the control and beta-2 groups 240 min after reperfusion. 
The myeloperoxidase activity (A) and TNF-α (B) were significantly higher in the 
control group. The data are presented as the means ± SD and were analyzed 






 Table 1.  Assessment of lung function in surviving recipients in the control (n = 5) and beta-2 (n = 5) groups.  
Time after transplantation, min 
(Before OP) 75 120 180 240      P-value  
Mean AoP, mmHg  
Control (123.2 ± 27.2) 98.0 ± 27.2 110.8 ± 26.6 86.6 ± 24.0 65.0 ± 38.8 
Beta-2 (114.6 ± 17.2) 102.0 ± 12.3 124.0 ± 13.4 118.2 ± 26.8 94.8 ± 36.5 0.17 
Mean PAP, mmHg 
Control (17.6 ± 2.0) 40.0 ± 11.7 41.8 ± 7.8 40.8 ± 6.7 27.0 ± 12.3 
Beta-2 (19.8 ± 2.1) 39.2 ± 14.4 38.2 ± 16.1 38.8 ± 16.2 37.6 ± 16.2 0.87 
Mean CVP, mmHg 
Control (5.6 ± 2.0) 6.4 ± 2.0 6.0 ± 2.5 6.8 ± 1.6 8.6 ± 4.7 
Beta-2 (5.4 ± 2.3) 9.0 ± 3.6 8.2 ± 3.4 8.0 ± 2.5 7.8 ± 3.5 0.47 
Mean LAP, mmHg 
Control (11.8 ± 1.9) 6.0 ± 1.8 5.2 ± 1.9 7.4 ± 2.3 7.4 ± 1.1 
Beta-2 (11.2 ± 2.7) 13.6 ± 7.4 10.8 ± 5.0 11.0 ± 6.5 10.2 ± 5.0 0.10 
Cardiac output, l/min 
Control (0.8 ± 0.2) 0.6 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.5 ± 0.3 
Beta-2 (0.8 ± 0.2) 1.1 ± 0.4 1.0 ± 0.1 0.9 ± 0.1 0.9 ± 0.2 0.087 
PVR, dyn･s･cm-5 x 103 
Control (569.4 ± 76.3) 4292.4 ± 1915.0 3844.8 ± 1212.7 3415.1 ± 1160.8 2717.3 ± 844.1  
Beta-2 (491.1 ± 169.4) 1939.6 ± 939.6 2174.0 ± 1151.2 2366.0 ± 942.7 2522.8 ± 1196.3 0.086 
PaO2, mmHg 
Control (569.8 ± 28.3) 349.4 ± 102.0 213.0 ± 160.6 139.2 ± 133.0 112.8 ± 87.3  
Beta-2 (623.6 ± 42.3) 625.2 ± 55.1 516.6 ± 161.1 537.0 ± 131.7 526.8 ± 130.2 < 0.001 
PaCO2, mmHg 
Control (17.2 ± 1.9) 31.9 ± 6.3 39.1 ± 4.5 48.5 ± 9.1 47.3 ± 6.0 
Beta-2 (20.9 ± 2.3) 32.1 ± 1.3 39.3 ± 6.3 39.5 ± 9.1 39.0 ± 8.6 0.24 
Dynamic compliance, ml/cmH2O 
Control (19.4 ± 1.1) 12.9 ± 1.3 13.8 ± 1.6 13.8 ± 1.6 13.6 ± 1.0 
Beta-2 (18.4 ± 1.8) 19.9 ± 2.6 18.7 ± 3.6 17.3 ± 3.1 16.9 ± 3.1 0.013 
OP = operation; AoP = aortic pressure; PAP = pulmonary artery pressure; CVP = central venous pressure; LAP = left atrial pressure; PVR = pulmonary 
vascular resistance. The data are shown as the means ± SD. P-values are for the differences between groups determined by a repeated measures 
analysis of variance between 75 and 240 min. 




Energy levels  Normal lung  
ATP (nmol/mg･dw) 4.20 ± 0.57a   
Energy chargeb  0.79 ± 0.02   
TANc (nmol/mg･dw) 6.21 ± 0.59   
 
B 
Energy levels  Control group   Beta-2 group  P-value 
ATP  2.21 ± 0.71  4.42 ± 1.35  0.012 
Energy charge 0.85 ± 0.05  0.87 ± 0.03  0.48 
TAN  2.83 ± 0.86  5.43 ± 1.51  0.027 
 
aThe data are presented as the means ± SD and were analyzed with unpaired 
t-tests.  
bEnergy charge = (ATP + 0.5ATP) / (ATP + ADP + AMP).  
cTAN = ATP + ADP + AMP.  
ADP = adenosine diphosphate; AMP = adenosine monophosphate; ATP = 
adenosine triphosphate; TAN = total adenosine nucleotides. 
 
 
